Clinical Trial Update: A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus [Phase 2]

View source ↗

Summary

This Phase 2 trial assessed the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of JNJ-53718678 in non-hospitalized adults wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• JNJ-53718678

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED | Results posted: 2022-06-28